Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-Controlled Proof-of-Concept Study of ANB020 in House Dust Mite Skin Challenge in Atopic Dermatitis
2016-002539-14Phase 2Completed
- Sponsor
- AnaptysBio, Inc.
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ANB020 arm with Placebo arm (2 arms). Primary endpoints: Cytokine levels in blister fluid after HDM skin challenge and Serum cytokine levels. Started Sep 2016; status: completed.
02
Drugs
etokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-002539-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002539-14.